How much funding has Shinobi Therapeutics raised?

Shinobi Therapeutics has raised $119.0M in total funding, most recently a Grant round.

Who are Shinobi Therapeutics's investors?

Shinobi Therapeutics's investors include Japanese Agency for Medical Research and Development (AMED), Yosemite, Mitsubishi UFJ Financial, F-Prime Capital, Eight Roads Ventures, EQT AB.

When was Shinobi Therapeutics founded?

Shinobi Therapeutics was founded in 2015.

Where is Shinobi Therapeutics headquartered?

Shinobi Therapeutics is headquartered in San Diego, California, United States.

What industry is Shinobi Therapeutics in?

Shinobi Therapeutics operates in Biotech, Therapeutics.

How many employees does Shinobi Therapeutics have?

Shinobi Therapeutics has 11-50 employees.

Shinobi Therapeutics

Silent. Precise. Potent.

San Diego, United States · Founded 2015 · $119.0M raised

Biotech

Therapeutics

Headquarters: San Diego, California
Employees: 11–50
Founded: 2015
Business Model: B2B

Website: shinobitx.com
Total Funding: $119.0M
Last Round: $59.0M GrantAug 2024
Rounds: 3

About

Shinobi Therapeutics is a Japan-US biotechnology company developing immune-evasive iPSC-derived cell therapies for cancer and autoimmune diseases. Its proprietary Katana platform engineers hypoimmune iPS cells that evade both innate and antibody-mediated immune rejection, enabling off-the-shelf allogeneic therapies without the need for immunosuppression. Rooted in research from Kyoto University and UCSF, Shinobi launched in 2023 with a $51M Series A.

Summary

Shinobi Therapeutics is a Biotech company based in San Diego, United States, founded in 2015. It has raised $119.0M in total across 3 rounds, most recently a $59.0M Grant round in Aug 2024. Investors include Japanese Agency for Medical Research and Development (AMED), Yosemite and Mitsubishi UFJ Financial.